BARCELONA, Spain, March 18, 2021 (GLOBE NEWSWIRE) -- Co-founded back in 2014 by VHIO’s Laura Soucek, CEO of the enterprise, and Marie-Eve Beaulieu, Chief Scientific Officer (CSO) of the company, ...

Built on over 20 years' research led by Laura Soucek, co-Director of the Vall d'Hebron Institute of Oncology's (VHIO) Preclinical and Translational Research Program, and Principal Investigator of VHIO ...

Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in most, if not all tumor types. Until recently, MYC has ...

An experimental drug has for the first time been shown to block a gene central to the growth of many cancers — in what could be a breakthrough. The treatment — known as OMO-103 — works by suppressing ...

BARCELONA, Spain, May 06, 2021 (GLOBE NEWSWIRE) -- Peptomyc, a Spanish clinical stage biotech company spin-off of the Vall d’Hebron Institute of Oncology (VHIO) and the Catalan Institute of Research ...

BARCELONA, Spain, July 27, 2023 (Newswire.com) - Peptomyc S.L., a biotech company specialized in the development of protein therapeutics for cancer treatment, announces that it has received full study ...

Preliminary results from a phase I clinical trial show that the first in class MYC inhibitor Omomyc (OMO-103) has few side effects, is tolerable, and stabilizes disease in some patients. Developed ...

PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial GlobeNewswire May 06, 2021 BARCELONA, Spain, May 06, 2021 (GLOBE NEWSWIRE) -- Peptomyc, a ...

BARCELONA, Spain, March 18, 2021 (GLOBE NEWSWIRE) — Co-founded back in 2014 by VHIO’s Laura Soucek, CEO of the enterprise, and Marie-Eve Beaulieu, Chief Scientific Officer (CSO) of the company, ...

BARCELONA, Spain, May 06, 2021 (GLOBE NEWSWIRE) -- Peptomyc, a Spanish clinical stage biotech company spin-off of the Vall d'Hebron Institute of Oncology (VHIO) and the Catalan Institute of Research ...